CCL2 and colorectal adenocarcinoma: Liraglutide did not interfere with the anti-inflammatory effects of BAR501, as indicated by stable IL-8, IL-1β, and CCL2 mRNA levels in HT29 cells (human colorectal adenocarcinoma cells), however, liraglutide did enhance ACE2 mRNA expression in co-cultures of HT29 and U937 cells (human monocyte cells) stimulated with LPS, thereby demonstrating its anti-inflammatory action.